Conference abstract
Study theme · illustration
Read the results alongside the study design, safety findings and limitations.

Who was studied?

43 screened; 39 received treatment, including 36 receiving PRaG, 30 receiving thymosin α1 loading, and 17 entering maintenance. The reported response denominator is 39.

What does the publication report?

ORR among 39 treated patients was 30.8%, with 4 complete and 8 partial responses. Median PFS was 4.2 months.

Safety findings

No grade ≥3 treatment-related adverse events were reported.

How should we interpret it?

Conference-level, non-randomized evidence. Linked reports may include the same participants and should not be counted as independent trials.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort. · DOI: 10.1200/JCO.2026.44.16_suppl.2516

Related publications from the same research program

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.